| CAS NO: | 1304701-57-2 |
| 包装 | 价格(元) |
| 500 μg | 电议 |
| 1mg | 电议 |
| Cas No. | 1304701-57-2 |
| 别名 | 依杜沙班杂质,DU-176-d6 |
| Canonical SMILES | ClC1=CN=C(NC(C(N[C@H]2CC[C@H](C(N(C([2H])([2H])[2H])C([2H])([2H])[2H])=O)C[C@H]2NC(C3=NC4=C(CN(C)CC4)S3)=O)=O)=O)C=C1 |
| 分子式 | C24H24ClD6N7O4S |
| 分子量 | 554.1 |
| 溶解度 | DMSO: Soluble,Methanol: Soluble |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Edoxaban-d6is intended for use as an internal standard for the quantification of edoxaban by GC- or LC-MS. Edoxaban is an orally bioavailable and potent inhibitor of factor Xa (Kis = 0.561 and 0.903 nM for free and complexed human factor Xa, respectively).1It is >10,000-fold selective for factor Xa over thrombin, FVIIa/sTF, FXIa, tPA, aPC, trypsin, plasmin, and chymotrypsin. Edoxaban prolongs prothrombin, activated partial thromboplastin, and thrombin clotting times in a concentration-dependent mannerex vivoin human plasma. Oral administration of edoxaban (0.5-12.5 mg/kg) reduces thrombus formation and prolongs prothrombin time in a dose-dependent manner in rat and rabbit models of venous stasis thrombosis. It also reduces thrombus formation in a rat model of platinum wire-induced venous thrombosis. Formulations containing edoxaban have been used to prevent stroke in patients with atrial fibrillation. 1.Furugohri, T., Isobe, K., Honda, Y., et al.DU-176b, a potent and orally active factor Xa inhibitor: In vitro and in vivo pharmacological profilesJ. Thromb. Haemost.6(9)1542-1549(2008) |
m.cnreagent.com